CytRx Corporation (Nasdaq:CYTR), a biopharmaceutical research and development company specializing in oncology, today announced encouraging overall survival (OS) results, the secondary endpoint, from its completed multicenter, randomized, open-label global Phase 2b clinical trial investigating the efficacy and safety of aldoxorubicin compared with doxorubicin as first-line therapy in subjects with metastatic, locally advanced or unresec… Read more »
Shares of Cytrx closed yesterday at $3.07 . CYTR has a 1-year high of $8.35 and a 1-year low of $2.08. The stock’s 50-day moving average is $2.76 and it’s 200-day moving average is $2.95.
On the ratings front, Cytrx has been the subject of a number of recent research reports. In a report published on January 20, analyst Yi Chen from Aegis Capital Corp. maintained a Buy rating on CYTR, with a price target of $12, which implies an upside of 290.9% from current levels.
CytRx Corp is a biopharmaceutical research and development company specializing in oncology. Its oncology pipeline includes three clinical-stage drug candidates in various stages of development: Aldoxorubicin, Tamibarotene, and Bafetinib.